Semaglutide

Fat LossFDA-approved GLP-1 receptor agonistEstablished

FDA-approved long-acting GLP-1 agonist for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). Weekly injection or daily oral tablet. Not WADA-prohibited (monitoring program).

Calculate Dose

For research use only.

Key Facts

CAS: 910463-68-2
Molecular Weight (MW): 4113.58 g/mol
Half-life: ~7 days
Unit: mcg
Administration Route: Subcutaneous (inj.) or oral (tablet)
Frequency: Once weekly
Last updated: 8/23/2026
Targets: GLP-1 receptor

Overview

FDA-approved long-acting GLP-1 agonist for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). Weekly injection or daily oral tablet. Not WADA-prohibited (monitoring program).

Protocol

Dosage Range: 0.25-2.4 mg weekly (weight loss) or 0.5-1.0 mg weekly (diabetes)
Frequency: Once weekly
Cycle: Long-term use as prescribed
Administration Route: Subcutaneous (inj.) or oral (tablet)
Reconstitution Guide: Prefilled pen - no reconstitution needed

Science

Mechanism of Action

GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. Fatty-acid acylation extends half-life to about 1 week.

Targets

GLP-1 receptor

Studies

SUSTAIN-6 CVOT— Journal/year not available
STEP 1 obesity trial— Journal/year not available

Benefits

Significant weight loss (up to 15% body weight)Improved glycemic control in type 2 diabetesReduced cardiovascular riskLower blood pressureImproved lipid profile